Mirum Pharmaceuticals ( (MIRM) ) has released its Q4 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its investors.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for rare diseases affecting both children and adults, with a portfolio that includes three approved medications and a robust pipeline of investigational drugs.
In its latest earnings report, Mirum Pharmaceuticals announced a significant increase in net product sales for 2024, totaling $336.4 million, and provided optimistic guidance for 2025 with expected sales between $420 million and $435 million. The company also highlighted key regulatory approvals and ongoing clinical trials that are expected to drive future growth.
The company reported strong growth across its three approved medicines, particularly LIVMARLI, which saw net sales of $213.3 million in 2024 and expanded its global reach to 30 countries. Additionally, Mirum achieved significant regulatory milestones, including the approval of CTEXLI in the U.S. for cerebrotendinous xanthomatosis and positive interim results for volixibat in clinical studies.
Despite a net loss of $87.9 million for the year, Mirum’s financial position remains strong with cash, cash equivalents, and investments totaling $292.8 million as of the end of 2024. The company continues to invest in research and development, with plans to initiate new clinical trials in 2025.
Looking ahead, Mirum Pharmaceuticals is poised for continued growth with a focus on expanding the reach of its existing products and advancing its pipeline of investigational treatments. The company remains committed to achieving its financial targets and delivering innovative therapies for patients with rare diseases.